aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using a set of physiological modulators. The Company has discovered approximately 300 Physiocrines, a class of naturally occurring proteins that promotes homeostasis. The Company’s Physiocrines have therapeutic application in various diseases characterized by tissue dysfunction, including severe diseases of the lung, gut, skin, brain and liver. The Company is engaged the development of Resolaris as an intravenous protein therapeutic for the treatment of rare myopathies with an immune component, or RMICs. The Company has developed Resolaris based on its discovery of the Resokine pathway in skeletal muscle tissue, an extracellular pathway in human skeletal muscle tissue associated with activities arising from various Physiocrine regions of the human histidine aminoacyl tRNA synthetase.